Evidence map›Paper›PMID 37907889›Full record

SynthesisBMC pulmonary medicine2023

Understanding the economic burden of chronic cough: a systematic literature review.

Vishal Bali, Ada Adriano, Aidan Byrne, Katherine G Akers, Andrew Frederickson, Jonathan Schelfhout

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Vishal BaliCenter for Observational and Real-World Evidence (CORE), Merck & Co., Inc, Rahway, NJ, USA. vishal.bali@merck.com.
Ada AdrianoOutcomes research, MSD, London, UK.ORCID http://orcid.org/0000-0001-8894-9007
Aidan ByrneOutcomes research, MSD, London, UK.
Katherine G AkersPRECISIONheor, New York, NY, USA.ORCID http://orcid.org/0000-0002-4578-6575
Andrew FredericksonPRECISIONheor, New York, NY, USA.
Jonathan SchelfhoutCenter for Observational and Real-World Evidence (CORE), Merck & Co., Inc, Rahway, NJ, USA.
Health Economics and Outcomes Research (United Kingdom) · GBMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic cough (CC) is associated with high healthcare resource utilization (HCRU) due to challenges in diagnosis and treatment and is anticipated to have a substantial economic impact. This systematic literature review (SLR) sought to identify evidence on the cost-effectiveness of treatments and the economic burden associated with CC. Electronic database searches were supplemented with searches of conference proceedings and health technology assessment body websites. Two independent reviewers assessed all citations for inclusion based on predefined inclusion/exclusion criteria. Key inclusion criteria were patient population with CC, and outcomes related to cost-effectiveness and HCRU and costs. After screening, one cost-effectiveness analysis was identified, alongside eight studies reporting HCRU and costs related to CC. Though evidence was limited, studies suggest that patients with CC incur higher costs and use more resources than those with acute cough. Types of resource use reported included healthcare contacts and prescriptions, diagnostic tests, referrals and specialist evaluations, and treatment use. There is a paucity of literature on HCRU and costs in CC, and very limited cost-effectiveness analyses. The economic burden appears higher in these patients however, without direct comparison to the general population it is difficult to determine the total impact. The increased burden is expected to be a result of the challenges with diagnosis and lack of approved treatments. However, limited conclusions can be drawn in the absence of further data. Future studies should endeavor to quantify the HCRU and cost attributable to patients with CC.

Indexed as

CoughFinancial StressChronic DiseaseCost-Benefit AnalysisHumansPatient Acceptance of Health CareBurdenChronic coughEconomic burdenRefractory chronic coughUnexplained chronic cough

Identifiers

PMID37907889
PMCPMC10619292
OpenAlexW4388080680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.